Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ziftomenib · Komzifti, KO-539

Small molecule · Inhibitor of menin (MEN1) · developed by Kura

Approved FDA, Nov 2025
KURA Developer
1 Registered trials

What is Ziftomenib?

Ziftomenib is a small-molecule menin inhibitor that blocks the interaction between menin and KMT2A. In NPM1-mutant leukemia, this disruption reduces the oncogenic activity of mutant NPM1 and promotes differentiation of leukemic cells. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Komzifti, KO-539
Drug type
Small molecule
Targets
menin (MEN1), lysine-specific methyltransferase 2A (KMT2A) (binding partner it blocks), nucleophosmin 1 (NPM1) mutation (biomarker)
Mechanism
Inhibitor of menin (MEN1)
Pathways
menin-KMT2A interaction and gene expression, leukemic cell differentiation
Therapy area
Oncology
Developer
Kura (KURA)
FDA status
Approved as Komzifti (November 13, 2025), NDA220305 · FDA label
UNII
4MOD1F4ENC

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 9, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07007312 Phase 3 Acute Myeloid Leukemia (AML) Recruiting KURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia (AML)

Other drugs acting on MEN1

More from Kura

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KURA page.

Follow KURA, the company behind Ziftomenib

See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KURA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.